A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Peking University First Hospital, Beijing

Phase

Safety & dosing

Sponsor

Peking University First Hospital

Collaborators

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital of Air Force Medicial University

Enrollment target

~53 participants

Started

August 2023

Primary completion

July 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Sex

Male only

Last updated December 2023